Literature DB >> 11009186

Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study.

J P Larsen1, K Karlsen, E Tandberg.   

Abstract

OBJECTIVE: To investigate the frequency of nonfluctuators in a community-based prevalence study of Parkinson's disease (PD) and to describe disability, non-motor problems, and health-related quality of life in patients with PD with and without motor fluctuations, and compare the findings to those of two control groups.
METHODS: The study involved 245 patients with PD who were participating in a prevalence study and two control groups (100 healthy elderly individuals and 100 patients with diabetes mellitus [DM]). Data were obtained through neurologic examination and a semistructured interview, and by the use of several questionnaires.
RESULTS: In this group of unselected patients with PD, 78% did not experience motor fluctuations. Mean duration of treatment with levodopa was 6.3 years. Patients with motor fluctuations had a lower age at onset of disease, longer duration of disease, and a higher daily levodopa dose than patients without fluctuations. Among the non-fluctuating patients, we found more dementia and a higher age at prevalence day. Disability (assessed by the Unified Parkinson's Disease Rating Scale subscales for activities of daily living and motor function and the Hoehn and Yahr stage) was similar in fluctuators and nonfluctuators. Depression, sleep disturbances, and fatigue were equally frequent in both patient groups. The occurrence of these difficulties was clearly more frequent among non-fluctuating patients with PD than among the control subjects.
CONCLUSION: Most patients in the general population who have PD do not experience dose-dependent motor fluctuations. Severity of motor disability and neuropsychiatric manifestations are as important in non-fluctuators as in fluctuators. Patients without motor fluctuations have more depression, sleep disturbances, fatigue, and a poorer health-related quality of life than patients with DM and healthy elderly individuals. This also underlines the importance of developing better management and treatment strategies for this group of patients with PD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11009186     DOI: 10.1002/1531-8257(200009)15:5<826::aid-mds1010>3.0.co;2-e

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

1.  Impact of fatigue in Parkinson's disease: the Fatigue Impact Scale for Daily Use (D-FIS).

Authors:  Pablo Martinez-Martin; Maria Jose Catalan; Julian Benito-Leon; Angel Ortega Moreno; Ivana Zamarbide; Esther Cubo; Nadeje van Blercon; Victor Campos Arillo; Margarita Pondal; Gurutz Linazasoro; Fernando Alonso; Pedro García Ruiz; Belen Frades
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

Review 2.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 3.  Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy.

Authors:  Benzi M Kluger; Lauren B Krupp; Roger M Enoka
Journal:  Neurology       Date:  2013-01-22       Impact factor: 9.910

4.  Psychiatric morbidity in patients with idiopathic Parkinson's disease: A cross-sectional study.

Authors:  Santhosh Kumar; Ajit Avasthi; Manish Modi; Sandeep Grover
Journal:  Ind Psychiatry J       Date:  2021-06-24

5.  Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.

Authors:  D J Brooks; H Sagar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

Review 6.  Psychiatric aspects of Parkinson's disease.

Authors:  Sandeep Grover; Mansi Somaiya; Santhosh Kumar; Ajit Avasthi
Journal:  J Neurosci Rural Pract       Date:  2015-01

7.  Quality of life in Parkinson's disease: A systematic review and meta-analysis of comparative studies.

Authors:  Na Zhao; Yuan Yang; Ling Zhang; Qinge Zhang; Lloyd Balbuena; Gabor S Ungvari; Yu-Feng Zang; Yu-Tao Xiang
Journal:  CNS Neurosci Ther       Date:  2020-12-28       Impact factor: 5.243

Review 8.  Quality of life in Parkinson's disease.

Authors:  J A Opara; W Brola; M Leonardi; B Błaszczyk
Journal:  J Med Life       Date:  2012-12-25

9.  Factors associated with motor complications in Parkinson's disease.

Authors:  Liis Kadastik-Eerme; Nele Taba; Toomas Asser; Pille Taba
Journal:  Brain Behav       Date:  2017-09-25       Impact factor: 2.708

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.